Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34661616.
- Also identified by DOI 10.1001/jamainternmed.2021.5989 and PMC identifier 8524351.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This exploratory study assesses estimated Medicare spending on 10 cancer drug indications that lacked overall survival benefit after receiving US Food and Drug Administration accelerated approval.
Medical subject headings
- Drug Approval
- Medicare
- Neoplasms
- United States Food and Drug Administration